Level Four Advisory Services’s China SXT Pharmaceuticals SXTC Stock Holding History

Level Four Advisory Services’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$5.26K	–	849
2023 Q3	$5.26K	Buy	+1	New	+$4.94K	﹤0.01%	742

Other funds holding SXTC

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Level Four Advisory Services's SXTC Position: Q4 2023 in Review

Level Four Advisory Services sold out of China SXT Pharmaceuticals (SXTC) in Q4 2023, closing a stake of 1 share — an estimated $5.26K sold.

Level Four Advisory Services first reported a position in SXTC in Q3 2023 and held it in 1 quarter. The position peaked at $5.26K in Q3 2023. 3 funds tracked by Wall St. Rank hold SXTC as of Q4 2023.

Level Four Advisory Services reported no remaining China SXT Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Level Four Advisory Services sold 1 China SXT Pharmaceuticals share in Q4 2023, an estimated $5.26K.
Level Four Advisory Services first reported a position in China SXT Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Level Four Advisory Services's China SXT Pharmaceuticals position peaked at $5.26K in Q3 2023.
3 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q4 2023.

Based on Level Four Advisory Services's 13F filing for Q4 2023, filed 8 Feb 2024.